Cardioprotection by a nonerythropoietic, tissue-protective peptide mimicking the 3D structure of erythropoietin

Proceedings of the National Academy of Sciences of the United States of America

Volumn 107, Issue 32, 2010, Pages 14357-14362

  Ueba, Hiroto ^a   Brines, Michael ^b   Yamin, Michael ^b   Umemoto, Tomio ^a   Ako, Junya ^a   Momomura, Shin Ichi ^a   Cerami, Anthony ^b   Kawakami, Masanobu ^a  

^a JICHI MEDICAL UNIVERSITY   (Japan)

^b Warren Pharmaceuticals Inc   (United States)

Author keywords

Apoptosis; Cardiomyocyte; Cytoprotection; Signal transduction

Indexed keywords

ATRIAL NATRIURETIC FACTOR; CELL PROTEIN; CREATINE KINASE; ERYTHROPOIETIN; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEIN HBSP; SMALL INTERFERING RNA; STAT3 PROTEIN; TRANSFORMING GROWTH FACTOR ALPHA; UNCLASSIFIED DRUG; CARDIOTONIC AGENT; PEPTIDE; PROTEIN KINASE B;

ANIMAL CELL; APOPTOSIS; ARTICLE; CELL CULTURE; CELL SURVIVAL; DOWN REGULATION; ENZYME ACTIVITY; HEART DILATATION; HEART FAILURE; HEART MUSCLE CELL; HEART PROTECTION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; SIGNAL TRANSDUCTION; ANIMAL; CHEMISTRY; CYTOLOGY; DRUG EFFECT; METABOLISM; MOLECULAR MIMICRY; PROTEIN CONFORMATION; RAT;

ANIMALS; APOPTOSIS; CARDIOTONIC AGENTS; ERYTHROPOIETIN; MOLECULAR MIMICRY; MYOCYTES, CARDIAC; PEPTIDES; PROTEIN CONFORMATION; PROTO-ONCOGENE PROTEINS C-AKT; RATS;

ANIMALIA; CRICETINAE; RATTUS;

EID: 77956291349     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1003019107     Document Type: Article

References (41)

1. Fisher JW (2003) Erythropoietin: Physiology and pharmacology update. Exp Biol Med (Maywood) 228:1-14.
2. Brines M, Cerami A (2008) Erythropoietin-mediated tissue protection: Reducing collateral damage from the primary injury response. J Intern Med 264:405-432.
3. Brines M, et al. (2004) Erythropoietin mediates tissue protection through an erythropoietin and common β-subunit heteroreceptor. Proc Natl Acad Sci USA 101:14907-14912.
4. Varet B, Casadevall N, Lacombe C, Nayeaux P (1990) Erythropoietin: Physiology and clinical experience. Semin Hematol 27(3, Suppl 3) 25-31.
5. Khorana AA, Francis CW, Culakova E, Lyman GH (2005) Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study. Cancer 104:2822-2829.
6. Leist M, et al. (2004) Derivatives of erythropoietin that are tissue protective but not erythropoietic. Science 305:239-242.
7. Brines M, et al. (2008) Nonerythropoietic, tissue-protective peptides derived from the tertiary structure of erythropoietin. Proc Natl Acad Sci USA 105:10925-10930.
8. McMurray J, Abdullah I, Dargie HJ, Shapiro D (1991) Increased concentrations of tumour necrosis factor in "cachectic" patients with severe chronic heart failure. Br Heart J 66:356-358.
9. Katz SD, et al. (1994) Pathophysiological correlates of increased serum tumor necrosis factor in patients with congestive heart failure. Relation to nitric oxide-dependent vasodilation in the forearm circulation. Circulation 90:12-16.
10. Ferrari R, et al. (1995) Tumor necrosis factor soluble receptors in patients with various degrees of congestive heart failure. Circulation 92:1479-1486.
11. Torre-Amione G, et al. (1996) Tumor necrosis factor-α and tumor necrosis factor receptors in the failing human heart. Circulation 93:704-711.
12. Habib FM, et al. (1996) Tumour necrosis factor and inducible nitric oxide synthase in dilated cardiomyopathy. Lancet 347:1151-1155.
13. Satoh M, et al. (1997) Inducible nitric oxide synthase and tumor necrosis factor-alpha in myocardium in human dilated cardiomyopathy. J Am Coll Cardiol 29:716-724.
14. Krown KA, et al. (1996) Tumor necrosis factor alpha-induced apoptosis in cardiac myocytes. Involvement of the sphingolipid signaling cascade in cardiac cell death. J Clin Invest 98:2854-2865.
15. Kubota T, et al. (1997) Dilated cardiomyopathy in transgenic mice with cardiac-specific overexpression of tumor necrosis factor-α. Circ Res 81:627-635.
16. Calvillo L, et al. (2003) Recombinant human erythropoietin protects the myocardium from ischemia-reperfusion injury and promotes beneficial remodeling. Proc Natl Acad Sci USA 100:4802-4806.
17. Parsa CJ, et al. (2003) A novel protective effect of erythropoietin in the infarcted heart. J Clin Invest 112:999-1007.
18. Fiordaliso F, et al. (2005) A nonerythropoietic derivative of erythropoietin protects the myocardium from ischemia-reperfusion injury. Proc Natl Acad Sci USA 102:2046-2051.
19. Mitsuhashi S, et al. (2003) Defect of delta-sarcoglycan gene is responsible for development of dilated cardiomyopathy of a novel hamster strain, J2N-k: Calcineurin/PP2B activity in the heart of J2N-k hamster. J Biochem 134:269-276.
20. Gottlieb SS, Kukin ML, Ahern D, Packer M (1989) Prognostic importance of atrial natriuretic peptide in patients with chronic heart failure. J Am Coll Cardiol 13:1534-1539.
21. Brines ML, et al. (2000) Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc Natl Acad Sci USA 97:10526-10531.
22. Erbayraktar S, et al. (2003) Asialoerythropoietin is a nonerythropoietic cytokine with broad neuroprotective activity in vivo. Proc Natl Acad Sci USA 100:6741-6746.
23. Gong H, et al. (2004) EPO and alpha-MSH prevent ischemia/reperfusion- induced down-regulation of AQPs and sodium transporters in rat kidney. Kidney Int 66:683-695.
24. Salahudeen AK, et al. (2008) Antiapoptotic properties of erythropoiesis-stimulating proteins in models of cisplatin-induced acute kidney injury. Am J Physiol Renal Physiol 294:F1354-F1365.
25. Sirén AL, et al. (2001) Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc Natl Acad Sci USA 98:4044-4049.
26. Bittorf T, Büchse T, Sasse T, Jaster R, Brock J (2001) Activation of the transcription factor NF-kappaB by the erythropoietin receptor: Structural requirements and biological significance. Cell Signal 13:673-681.
27. Jonassen AK, Sack MN, Mjøs OD, Yellon DM (2001) Myocardial protection by insulin at reperfusion requires early administration and is mediated via Akt and p70s6 kinase cell-survival signaling. Circ Res 89:1191-1198.
28. Higuchi Y, et al. (2006) Cardioprotection afforded by NF-kappaB ablation is associated with activation of Akt in mice overexpressing TNF-a. Am J Physiol Heart Circ Physiol 290:H590-H598.
29. Miyata S, et al. (2006) Autophagic cardiomyocyte death in cardiomyopathic hamsters and its prevention by granulocyte colony-stimulating factor. Am J Pathol 168:386-397.
30. Moon C, et al. (2006) Erythropoietin, modified to not stimulate red blood cell production, retains its cardioprotective properties. J Pharmacol Exp Ther 316:999-1005.
31. Wang L, Zhang Z, Wang Y, Zhang R, Chopp M (2004) Treatment of stroke with erythropoietin enhances neurogenesis and angiogenesis and improves neurological function in rats. Stroke 35:1732-1737.
32. Ransome MI, Turnley AM (2007) Systemically delivered Erythropoietin transiently enhances adult hippocampal neurogenesis. J Neurochem 102:1953-1965.
33. Harder Y, et al. (2009) Erythropoietin reduces necrosis in critically ischemic myocutaneous tissue by protecting nutritive perfusion in a dose-dependent manner. Surgery 145:372-383.
34. Erbayraktar Z, et al. (2009) Nonerythropoietic tissue protective compounds are highly effective facilitators of wound healing. Mol Med 15:235-241.
35. Villa P, et al. (2003) Erythropoietin selectively attenuates cytokine production and inflammation in cerebral ischemia by targeting neuronal apoptosis. J Exp Med 198:971-975.
36. Coleman TR, et al. (2006) Cytoprotective doses of erythropoietin or carbamylated erythropoietin have markedly different procoagulant and vasoactive activities. Proc Natl Acad Sci USA 103:5965-5970.
37. Chung ES, Packer M, Lo KH, Fasanmade AA, Willerson JT; Anti-TNF Therapy Against Congestive Heart Failure Investigators (2003) Randomized, double-blind, placebo-controlled, pilot trial of infliximab, a chimeric monoclonal antibody to tumor necrosis factor-α, in patients with moderate-to-severe heart failure: Results of the anti-TNF Therapy Against Congestive Heart Failure (ATTACH) trial. Circulation 107:3133-3140.
38. Mann DL, et al. (2004) Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL). Circulation 109:1594-1602.
39. Iwaki K, Sukhatme VP, Shubeita HE, Chien KR (1990) Alpha- and beta-adrenergic stimulation induces distinct patterns of immediate early gene expression in neonatal rat myocardial cells. fos/jun expression is associated with sarcomere assembly; Egr-1 induction is primarily an alpha 1-mediated response. J Biol Chem 265:13809-13817.
40. Tamamori-Adachi M, et al. (2003) Critical role of cyclin D1 nuclear import in cardiomyocyte proliferation. Circ Res 92:e12-e19.
41. Ueba H, et al. (2005) Glimepiride induces nitric oxide production in human coronary artery endothelial cells via a PI3-kinase-Akt dependent pathway. Atherosclerosis 183:35-39.